Observational Study of Apremilast in Patients With Psoriasis in The Netherlands
- Conditions
- Psoriasis
- Registration Number
- NCT02652494
- Lead Sponsor
- Amgen
- Brief Summary
This is a multicenter, prospective, non-interventional, observational single arm study.
Two-hundred patients will be recruited in the Netherlands over a one year period. In all cases, the decision to treat the patient with apremilast will be made prior to the decision to enter the subject into this study. Treatment will be according to routine clinical practice and based on recommendations as per the SPC of apremilast (Otezla®). Recruitment will continue until 200 patients have entered the study. Each patient will be followed for 12 months.
- Detailed Description
Baseline Demographics, disease characteristics and medication history prior to start of treatment with apremilast will be collected. Patients will be asked to complete baseline DLQI, SF36, EQ5D, TSQM,WPAI and PBI questionnaires. Photographs of the finger nails will be taken.
Follow-up visits Follow-up assessments will take place at the regularly scheduled outpatient visits at 6 and 12 months (+/- 1 month) after initiation of apremilast.
* Skin-specific disease measures (Psoriasis Activity and Severity Index (PASI), (static) Physician Global Assessment (sPGA), Body Surface Area (BSA))
* Patients will be asked to complete the following questionnaires:
* DLQI
* TSQM
* EQ5D
* SF36- Itch Visual Analog Scale (VAS)
* WPAI Work Productivity and Activity Index
* Patient Benefit Index PBI
End of treatment Upon discontinuation of treatment with apremilast, the date, the dose and reason for discontinuation will be documented.
AE monitoring All patients will be monitored for adverse events throughout the study.
From the time of the patient signing informed consent until treatment with apremilast is permanently abrogated, all non-serious adverse events that are considered related to apremilast and all Serious Adverse Events (SAEs) regardless of causality will be reported.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 154
- Patients ≥ 18 years of age who understand and voluntarily sign an informed consent form.
- Patients starting treatment for psoriasis with apremilast in clinical practice.
- Refusal to participate in the study.
- Women who are pregnant or breast-feeding.
- Hypersensitivity to the active substance or to any of the excipients.
- Prior exposure to apremilast
- Psoriatic arthritis treated by a rheumatologist in the previous year
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with Dermatology Life Quality Index (DLQI) improvement in DLQI ≥ 5 points Up to approximately 12 months The Dermatology Life Quality Index or DLQI is a dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions.
Percentage of patients with Dermatology Life Quality Index (DLQI) ≤ 5 points Up to approximately 12 months The Dermatology Life Quality Index or DLQI is a dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions.
- Secondary Outcome Measures
Name Time Method Changes in body surface area (BSA)at 6 and 12 months treatment Up to approximately 12 months BSA (Body Surface Area): severity is defined by how much of the body surface area is affected.
Changes in treatment satisfaction questionnaire for medication (TSQM) at 6 and 12 months treatment Up to approximately 12 months The TSQM questionnaire is a general measure of treatment satisfaction across medication types and patient conditions.
Change in itch at 6 and 12 months treatment using the itch Visual Analog Scale (VAS) Up to approximately 12 months Itch VAS is a simple assessment of the itch severity using a visual analogue scale
Changes in psoriasis area and severity index (PASI) at 6 and 12 months treatment Up to approximately 2 months PASI score is a tool used to measure the severity and extent of psoriasis (Psoriasis Area and Severity Index).
Changes in generic quality of life at 6 and 12 months treatment using EuroQol-5 dimensions (EQ-5D) Up to approximately 12 months EQ-5D is a standardized instrument for use as a measure of health outcome in a wide range of health conditions and treatment
Changes in static physician global assessment (sPGA) at 6 and 12 months treatment Up to approximately 12 months sPGA: assessment by physician to classify disease activity in a consistent manner
Reasons for discontinuation of apremilast Up to approximately 12 months Rate and reasons for discontinuation of apremilast within 12 months of start
Changes in generic quality of life at 6 and 12 months treatment Short Form 36 (SF-36v2) health survey Up to approximately 12 months The SF-36v2® Health Survey measures functional health and well-being from the patient's point of view. It can be used across age (18 and older), disease, and treatment group.
Baseline characteristics of patients initiating apremilast treatment Up to approximately 1 month Characteristics at baseline of patient initiating apremilast treatment
Trial Locations
- Locations (12)
Antonius Ziekenhuis Sneek
🇳🇱Sneek, Friesland, Netherlands
Bravis Ziekenhuis
🇳🇱Bergen op Zoom, North-Brabant, Netherlands
Amphia
🇳🇱Breda, North-Brabant, Netherlands
Maxima MC
🇳🇱Veldhoven, North-Brabant, Netherlands
Centrum Oosterwal
🇳🇱Alkmaar, North-Holland, Netherlands
Spaarne Gasthuis
🇳🇱Hoofddorp, North-Holland, Netherlands
Zuyderland MC
🇳🇱Sittard, Limburg, Netherlands
Radboud UMC
🇳🇱Nijmegen, Gelderland, Netherlands
Zorggroep Twente
🇳🇱Hengelo, Gelderland, Netherlands
Maasstad Ziekenhuis
🇳🇱Rotterdam, South Holland, Netherlands
Meander MC
🇳🇱Amsersfoort, Utrecht, Netherlands
TweeSteden Ziekenhuis
🇳🇱Tilburg, North Brabant, Netherlands